PEPTONIC medical Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Anna Linton

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.004%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	1.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Anna Linton (53 yo)

less than a year

Permanencia

Ms. Anna Linton is Chief Executive Officer of Pharmiva AB (publ) from August 2022. She is Chief Executive Officer since February 06, 2024 at PEPTONIC medical AB (publ). She has several years of experience...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tarek Shoeb	Director	1.8yrs	SEK 117.00k	0.76% € 229.1k
Anders Blom	Chairman of the Board	1.4yrs	SEK 229.00k	4.08% € 1.2m
Kristina Ingvar	Director	less than a year	sin datos	0.0083% € 2.5k
Mika Kurjanen	Board Member Lune Group Oy Ltd	no data	sin datos	sin datos
Daniel Rudeklint	Director	no data	SEK 200.00k	0.0080% € 2.4k

1.4yrs

Permanencia media

53.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 28L no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

PEPTONIC medical Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

Less than half of directors are independent

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released

Peptonic Medical AB (publ) Strengthens U.S. Market Presence with Full-Scale Launch of VagiVital

PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Shareholder dilution

PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

New minor risk - Financial data availability

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) to Report Q1, 2024 Results on May 07, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

New major risk - Share price stability

Peptonic Medical AB (Publ) Announces Patented Apoteket Offering in 293 Apoteket Stores

Third quarter 2023 earnings released

New major risk - Share price stability

Second quarter 2023 earnings released

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

District Court Rejects the Claim for A Corporate Fine and Acquits All in Insider Case Against Peptonic Medical AB (Publ)

PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.

Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).

Peptonic Medical AB (Publ) Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.15 loss per share (vs kr0.39 loss in FY 2021)

Third quarter 2022 earnings released

High number of new and inexperienced directors

Third quarter 2022 earnings released

PEPTONIC medical AB (publ) Ongoing Applications for the Intimate Wash and for the Treatment of Fungal Infection Has Received Positive Statements from the International Review

Peptonic Medical AB (Publ) Announces Vagivital® Al Self-Test for Amniotic Fluid Leakage Detection Is Now Commercially Available for Sale in Its Own Online Store

Peptonic Medical's Ongoing Application for Vestibulitis Patent Receives Positive Opinion from the International Review

Second quarter 2022 earnings released: kr0.037 loss per share (vs kr0.064 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released

No independent directors

Hans von Celsing, Leni Ekendahl, Marianne Östlund and Anna Tenstam Declines Re-Election to the Board of Directors of PEPTONIC medical AB (publ)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PEPTONIC medical AB (publ) to Report Q1, 2022 Results on May 12, 2022

Peptonic Medical Introduces the Vagivital Range of Products to the US Market

Third quarter 2021 earnings released

PEPTONIC Initiates Non-Exclusive Negotiations Regarding a Possible Acquisition of All Assets in CommonSense Ltd (Israel)

Second quarter 2021 earnings released: kr0.064 loss per share (vs kr0.051 loss in 2Q 2020)

Peptonic Medical Gets Approval to Start a Clinical Trial for the Treatment of Vaginal Fungal Infections with an Adapted Version of VagiVital AktivGel

Peptonic Medical AB (Publ) Announces Latest Clinical Study with Vagivita

Peptonic Medical (publ) to Launch New Innovative Intimate Care Range Under Lunette Brand, Bringing Special Nordic Ingredients Down There

First quarter 2021 earnings released

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad